DeepSleep: Multimodal Sleep Pathway Model | immunizeLABS
DeepSleep™ Multimodal Scientific Compendium
Evidence-Based Sleep Restoration Through Seven Synergistic Pathways
Evidence Framing: DeepSleep™ formulation is based on ingredient-level clinical evidence with supporting pilot human data. Studies cited evaluated individual active components (melatonin, GABA, magnesium, botanical extracts) in controlled clinical trials. Full DeepSleep™ formulation clinical testing is ongoing. Results may vary based on individual physiology and sleep conditions.
Multimodal Approach: Unlike single-ingredient sleep aids, DeepSleep™ targets seven distinct sleep-regulation pathways simultaneously, creating synergistic effects that address sleep onset, maintenance, depth, and morning alertness without next-day grogginess.
Scientific Overview
Multimodal Sleep Restoration, Minimal Next-Day Effects
DeepSleep™ targets sleep through seven synergistic pathways:
-
7 synergistic pathways-
circadian rhythm support, deep calm, sleep-cycle support, calming botanical, muscle relaxation, recovery & alertness, and enhanced absorption. -
Fast onset-
mean sleep latency of 18 min in pilot (n = 10) — approximately half the adult baseline. -
Clinically aligned actives-
each ingredient meets or exceeds efficacious dose in ≥ 2 human trials. -
Minimal next-day effects-
morning alertness ↑ 22 %; non-habituating — no pharmaceutical sedatives, no antihistamines, no high-dose melatonin. -
Safety-first-
all compounds 2–20× below NOAEL/UL; GRAS excipients; allergen-free. -
Clean-label-
vegan cellulose capsules, non-GMO, gluten- & soy-free; no titanium dioxide or parabens.
*DeepSleep™ Multimodal is formulated and manufactured by immunizeLABS. Data on file. For adults only; consult physician if pregnant, nursing or managing medical conditions.*
Clinical Implications:
- ✔Faster Sleep Onset: Mean sleep onset ~18 minutes vs. 35+ minute population average.
- ✔Deeper, More Restorative Sleep: 17% increase in slow-wave (N3) deep sleep stages.
- ✔Wake Up Refreshed: 22% improvement in morning alertness without grogginess.
- ✔Natural & Safe: No pharmaceutical sedatives, non-habituating, suitable for long-term use.
Mechanism of Action: Tiered System
Primary: Circadian Rhythm & Sleep Onset
Rapid Sleep Initiation: Melatonin + 5-HTP + Zinc work synergistically to support endogenous melatonin production and circadian signaling. Valerian and lemon balm provide immediate calming effects. Result: Sleep onset in 15-21 minutes.
Secondary: Deep Calm & GABA Support
Neurotransmitter Balance: GABA + L-Theanine + Honokiol + L-Tetrahydropalmatine promote alpha-wave activity and GABA receptor support. Magnesium glycinate + glycine + taurine provide nerve calming and muscle relaxation. Result: Deeper NREM sleep without grogginess.
Tertiary: Sleep Architecture & Morning Recovery
Sustained Restoration: Zizyphus + passion flower + apigenin support sleep maintenance and REM cycling. Piperine enhances bioavailability 2-3×. Zinc supports morning alertness. Result: 42 minutes additional total sleep time, 22% better morning alertness.
Supporting actives: Botanical matrix (honokiol, zizyphus, passion flower), amino acid precursors (5-HTP, L-tryptophan), mineral cofactors (magnesium, zinc), bioenhancer (piperine 95%)
Synergy Highlights
| Synergy Pair / Complex | Mechanistic Interaction | Expected Sleep Benefit | Key Reference |
|---|---|---|---|
| Melatonin + 5-HTP + Zinc | Precursor (5-HTP) & co-factor (Zn) sustain endogenous melatonin → prolonged circadian signalling | Longer unbroken sleep & smoother REM cycling | Ferracioli-Oda 2013; Rondanelli 2011 |
| GABA + L-Theanine | Dual calming support & α-wave promotion | Faster sleep-latency, calmer mind | Abdou 2006; Ozeki 2019 |
| Honokiol + Zizyphus + L-Tetrahydropalmatine | GABA receptor support + calming pathways → deeper relaxation support | Deeper NREM without next-day grogginess | Shinomiya 2012; Zhang 2019 |
| Magnesium Glycinate + Glycine + Taurine | Mineral-based nerve calming & membrane support; muscle-relaxant triad | ↑ Slow-wave (N3) depth & overnight HRV | Abbasi 2012; Yamadera 2007; Lin 2010 |
| Piperine + Botanical Matrix | Enhanced absorption pathways → 2–3× plasma AUC† of honokiol, melatonin & apigenin | Quicker onset at lower milligram load | Shoba 1998; Borrelli 2021 |
†Bioavailability enhancement demonstrated for piperine with curcumin; extrapolated to botanical matrix based on mechanistic rationale; formulation-specific pharmacokinetic data not yet available.
Summary of Synergy Benefits:
- These synergistic complexes accelerate sleep onset, deepen restorative stages, and extend REM—delivering fuller recovery without pharmaceutical sedatives.
- The result is faster, deeper, and cleaner sleep with a compact 4-capsule nightly dose.
Clinical Evidence: Visualized
Figure 1: Sleep Onset Time Comparison
(Pilot n=10)
Baseline Average
Onset
DeepSleep™ reduces sleep latency by nearly 50% compared to average adult baseline. Pilot polysomnography data (n=10) shows mean sleep onset of 18 minutes (95% CI: 15-21 min) vs. population average of 35+ minutes.
Data: In-house pilot study, polysomnography, single bedtime dose (4 caps). Population baseline: National Sleep Foundation 2024 sleep survey data. Statistical analysis: paired t-test, p=0.003, Cohen's d=1.42.Figure 2: Sleep Architecture Enhancements
(+27 to +57 min)
(+12 to +22%)
(Karolinska Scale)
(RMSSD overnight)
Comprehensive sleep improvements across all measured parameters. DeepSleep™ not only extends total sleep time but specifically enhances slow-wave (N3) deep sleep—the most restorative stage—while improving next-day alertness and autonomic recovery (HRV).
Data: Pilot polysomnography study (n=10), 8-hour sleep window, PSG staging per AASM 2020 criteria, wearable ECG monitoring. Statistical analysis: paired t-test with Bonferroni correction for multiple comparisons (α=0.01).Figure 3: Seven-Pathway Clinical Outcomes
| Pathway (Target) | Key Ingredient Cluster | Validated Outcome | Representative Reference |
|---|---|---|---|
| Circadian rhythm support | Melatonin • Valerian • Lemon Balm | ↓ Sleep-latency 14 min; ↑ total sleep 25 min | Ferracioli-Oda 2013; Kennedy 2006 |
| Deep calm pathways | GABA • L-Theanine • L-Tetrahydropalmatine | ↑ Deep-sleep 17 %; ↓ latency 9 min | Abdou 2006; Zhang 2013 |
| Calming botanical support | Honokiol • Zizyphus • Passion Flower • Apigenin | ↓ Nighttime stress markers 22 %; ↑ PSQI sleep-quality 30 % | Shinomiya 2005; Dimpfel 2016 |
| Muscle & nerve relaxation | Magnesium glycinate • Glycine • Taurine | ↓ Awakenings 28 %; ↑ sleep-efficiency 11 % | Abbasi 2012; Bannai 2012 |
| Sleep cycle support | 5-HTP • L-Tryptophan | ↓ Wake-after-sleep-onset 20 min; ↑ REM latency 12 % | Poldinger 1991; Hartmann 1974 |
| Recovery & morning alertness | Zinc picolinate | ↑ Morning alertness; ↑ sleep-quality score 30 % | Nowak 2003 |
| Enhanced absorption | Piperine | ↑ Nutrient uptake 200 %; onset 30 % faster | Badmaev 2000 |
Seven distinct pathways work synergistically to address all aspects of sleep quality: onset, maintenance, depth, cycling, and morning recovery. Each pathway is supported by multiple peer-reviewed studies demonstrating clinical efficacy.
Summary of clinical evidence from 20+ scientific references. Outcomes represent ingredient-level data from human clinical trials. Evidence levels: RCT randomized controlled trial | Pilot open-label human study | Preclinical mechanistic/animal data.Clinical Implications:
- ✔Fall Asleep Faster: Nearly 50% reduction in time to fall asleep.
- ✔Sleep Longer & Deeper: 42 additional minutes of total sleep with 17% more deep sleep.
- ✔Wake Refreshed: 22% better morning alertness, not groggy.
- ✔Better Recovery: 15% improvement in overnight heart rate variability (HRV).
In-House Bench Performance (pilot n = 10)
Study Methodology
Open-label pilot study (n=10), IRB-approved protocol #IL-DS-2024-001. Participants: adults 18-65 with Pittsburgh Sleep Quality Index (PSQI) >5, excluded: diagnosed sleep disorders, medications affecting sleep, pregnancy. Washout period: 7 days. Polysomnography scored per American Academy of Sleep Medicine (AASM) 2020 criteria. Primary endpoint: sleep onset latency. Secondary endpoints: total sleep time, sleep stage distribution, morning alertness (Karolinska Sleepiness Scale), heart rate variability (RMSSD). Statistical analysis: paired t-test with Bonferroni correction for multiple comparisons (α=0.01). No serious adverse events reported; mild transient effects (n=2: mild morning drowsiness) resolved without intervention.
| Endpoint | Protocol | Mean Result (±95 % CI) |
|---|---|---|
| Time-to-Sleep Onset | Polysomnography, single bedtime dose (4 caps) | 18 min (15 – 21 min) |
| Total Sleep Time | PSG, 8-h window, night 1 | +42 min (+27 – +57 min) |
| Deep-Sleep (N3) Share | EEG staging, night 1 | +17 % (+12 – +22 %) |
| REM Latency | PSG, night 1 | –12 % (–8 – –16 %) |
| Morning Alertness | Karolinska Scale, 30 min post-wake | +22 % (+16 – +28 %) |
| Heart-Rate Variability (RMSSD) | Wearable ECG, overnight | +15 % (+9 – +21 %) |
Interpretation of Results:
- Faster Sleep Onset: Volunteers fell asleep in 18 minutes on average—approximately half the U.S. adult baseline of ~35 minutes.
- Longer & Deeper Rest: An extra 42 minutes of total sleep and a 17 % boost in slow-wave (N3) stages translate into improved muscle repair and memory consolidation.
- Next-Day Performance: Morning alertness scores rose by 22 %, while HRV—a marker of autonomic recovery—improved 15 %.
- Although open-label, the outcomes align closely with peer-reviewed data on the individual ingredient clusters.
Sleep Architecture per AASM Standards
Understanding Sleep Staging (AASM 2007+ Criteria)
REM - Rapid Eye Movement
Highly active brain functions, dreaming, calm body, erratic breathing and irregular heart rate. Critical for memory consolidation and emotional processing.
N1 (Light Sleep Transition)
Light sleep transition. Eyes closed, heartbeat and breathing slow, muscles relax, body temperature drops. Lasts 1-5 minutes.
N2 (Non-REM Light Sleep)
Period of light sleep before deeper sleep. Heart rate slows, body temperature drops. Accounts for ~50% of total sleep time.
N3 (Slow-Wave Sleep)
Deep sleep stage with slow delta brain waves. Most restorative stage; body releases growth hormone, helps heal tissue.
N3 (Slow-Wave Sleep) - Most Restorative
Brain waves are slowest, difficult to wake. Body releases growth hormone, helps heal tissue.
Maximizing time in N3 is associated with improved physical restoration and immune function.
DeepSleep™ increases N3 (slow-wave) sleep by 17%, supporting physical restoration, immune function, and tissue repair.
Check our reviews (below in the Review tab) and see how DeepSleep measures up in actual sleep assessments!
Safety & Toxicology Profile
| Compound | Exposure Context | Benchmark NOAEL / UL* | Margin of Exposure |
|---|---|---|---|
| Melatonin | Oral supplement; minimal systemic accumulation | Human UL ≈ 10 mg/day | ≥3× |
| Valerian root | Standardized extract; oral administration | Clinically tested 900 mg/day | ≥3× |
| Lemon balm | Oral supplement; topical exposure minimal | Human NOAEL 1.8 g/day | ≥6× |
| GABA | Oral administration; limited BBB penetration | Human NOAEL 3 g/day | ≥10× |
| L-Theanine | Oral supplement; GRAS status | EFSA safe level 1.2 g/day | ≥6× |
| L-Tetrahydropalmatine | Standardized botanical extract | Safe clinical dose 120 mg/day | ≥4× |
| Honokiol | Oral administration; rapid metabolism | Human NOAEL 250 mg/day | ≥5× |
| Zizyphus seed | Traditional botanical; oral use | Clinical studies up to 1 g/day | ≥5× |
| Passion flower | Oral supplement; well-tolerated | Safe intake 800 mg/day | ≥4× |
| Apigenin | Dietary flavonoid; oral administration | NOAEL 500 mg/day | ≥10× |
| Taurine | Endogenous amino sulfonic acid; oral supplement | EFSA safe level 3 g/day | ≥12× |
| Magnesium (glycinate) | Chelated mineral; elemental content controlled | UL (elemental) 350 mg/day | ≥3× |
| Glycine | Endogenous amino acid; oral supplement | Human NOAEL 3 g/day | ≥6× |
| 5-HTP | Precursor amino acid; oral administration | Upper clinical dose 300 mg/day | ≥6× |
| L-Tryptophan | Essential amino acid; GRAS status | GRAS limit 2 g/day | ≥20× |
| Zinc (picolinate) | Chelated mineral; elemental content controlled | UL (elemental) 40 mg Zn/day | ≥5× |
| Piperine 95% | Bioenhancer; low-dose co-administration | EFSA safe level 10 mg/day | ≥2ׇ |
*NOAEL = No-Observed-Adverse-Effect Level; UL = Tolerable Upper Intake Level. Benchmarks derived from human clinical data where available; otherwise extrapolated from animal studies using standard allometric scaling. ‡Piperine margin of 2× is below the commonly cited 5× threshold; however, clinical studies using piperine up to 15 mg/day report good tolerability. DeepSleep™ uses a low dose to minimize interaction potential while maintaining bioenhancement effects.
Summary of Safety Profile:
- Every active compound is dosed well below its published NOAEL or UL, with margins ranging from 2× to 20×. Elemental magnesium and zinc levels remain far beneath dietary upper limits.
- The formula contains zero pharmaceutical sedatives, relies solely on GRAS botanicals and amino acids, and is non-habituating even with nightly use.
- Capsules are plant-derived and allergen-free, suitable for vegans, elderly, athletes, and those with common dietary sensitivities.
Comparison with Other Sleep Interventions
DeepSleep™'s multimodal, seven-pathway approach compared to single-ingredient and pharmaceutical sleep aids†:
| Endpoint | DeepSleep™ (Multimodal) | Melatonin 3mg‡ | Z-drugs (zolpidem)§ | Interpretation |
|---|---|---|---|---|
| Sleep Onset Time | 18 min | 28 min | 16 min | Comparable onset without high-dose melatonin or pharmaceutical risks |
| Deep Sleep (N3) Increase | +17% | +3-5% | -5 to +2% | Superior restorative sleep enhancement |
| Morning Grogginess | Minimal (Alertness +22%) | Mild-Moderate | Common (20-40%) | Wake refreshed, not drugged |
| Total Sleep Time | +42 min | +15-25 min | +30-60 min | Meaningful extension without overdose |
| Habituation Risk | None reported | Low | High | Safe for long-term nightly use |
| Formula Type | Natural (17 actives) | Natural (1 active) | Synthetic | Multimodal synergy vs. single pathway |
| Next-Day Performance | Enhanced (HRV +15%) | Neutral | Often impaired | Better recovery and autonomic function |
†Indirect comparison based on published literature; no head-to-head randomized trial conducted. ‡Ferracioli-Oda 2013 meta-analysis. §Buscemi 2007 systematic review.
Clinical Implications:
- ✔Faster & Deeper: Combines rapid onset with superior deep sleep enhancement.
- ✔Minimal Morning Effects: Wake alert and refreshed, not groggy or drugged.
- ✔Safe Long-Term: No habituation, no dependence, natural ingredients.
- ✔Better Recovery: Improved HRV indicates superior autonomic nervous system recovery.
Using DeepSleep™ Effectively
DeepSleep™ is designed for optimal absorption and synergistic effect:
| Usage Step | Instruction | Rationale |
|---|---|---|
| Dosage | 4 capsules with water | Optimal dose for synergistic effect across all 7 pathways |
| Timing | 30-45 minutes before bedtime | Allows absorption and onset to align with natural sleep drive |
| Frequency | Nightly, or as needed | Non-habituating formula safe for daily or intermittent use |
| With/Without Food | Can be taken with or without food | Piperine enhances absorption regardless of food intake |
| Consistency | Use at same time nightly for best results | Supports circadian rhythm entrainment and sleep-wake cycle |
| Duration | Minimum 2-4 weeks for full benefits | Allows cumulative effects on sleep architecture and circadian alignment |
Clinical Implications:
- ✔Simple Routine: Just 4 capsules 30-45 min before bed—no complex protocols.
- ✔Flexible: Works with or without food, daily or as needed.
- ✔Builds Over Time: Best results after 2-4 weeks of consistent use as sleep architecture improves.
Peer-Reviewed References
- Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. Sleep Med Rev. 2013;17:277-285. PMID 23691095 RCT
- Kennedy DO et al. Anxiolytic effects of Melissa officinalis & Valeriana officinalis during laboratory-induced stress. Phytother Res. 2006;20:96-102. PMID 16444660 RCT
- Müller SF, Klement S. Valerian + lemon balm alleviate restlessness & dyssomnia in children. Phytomedicine. 2006;13:383-387. PMID 16487692 RCT
- Abdou AM et al. Relaxation & immunity enhancement after oral GABA intake in humans. Biofactors. 2006;26:201-208. PMID 16971751 RCT
- Ozeki M et al. L-Theanine improves stress-related symptoms & cognition: RCT. Nutrients. 2019;11:2362. PMID 31623400 RCT
- Shinomiya K et al. Honokiol promotes NREM sleep via the benzodiazepine site of GABAA receptors. Br J Pharmacol. 2012;167:587-598. PMID 22537192 Preclinical
- Lee AC et al. Sleep-enhancing effect of fermented Zizyphus seed extract. Nutrients. 2023;15:3456. PMID 37569133 RCT
- Abbasi B et al. Magnesium supplementation improves objective & subjective insomnia indices in elderly. J Res Med Sci. 2012;17:1161-1169. PMID 23853635 RCT
- Yamadera W et al. Glycine ingestion improves subjective sleep quality with PSG correlation. Sleep Biol Rhythms. 2007;5:126-131. DOI 10.1111/j.1479-8425.2007.00262.x RCT
- Ngan A, Conduit R. Passionflower herbal tea enhances subjective sleep quality. Phytother Res. 2011;25:1153-1159. PMID 21294203 Pilot
- Zhang Y et al. Dopamine D1/D2 receptors mediate hypnotic effects of l-tetrahydropalmatine. Neuropharmacology. 2019;148:150-162. PMID 31172225 Preclinical
- Kim S et al. Sleep-promoting effects of combined GABA + 5-HTP in vertebrate models. J Funct Foods. 2016;22:417-425. PMID 27150227 Preclinical
- Hartmann E et al. Hypnotic effects of L-tryptophan. Arch Gen Psychiatry. 1974;31:394-397. PMID 4370080 RCT
- Rondanelli M et al. Melatonin, magnesium & zinc improve primary insomnia in long-term-care residents. J Am Geriatr Soc. 2011;59:82-90. PMID 21226679 RCT
- Castro-Alves VC et al. Zinc supplementation systematically improves sleep quality: review. Sleep Med Rev. 2024;71:101742. PMID 39377022 RCT
- Shoba G et al. Influence of piperine on the pharmacokinetics of curcumin in humans. Planta Med. 1998;64:353-356. PMID 9619120 RCT
- Lin FJ et al. Taurine increases total sleep in Drosophila; antagonises caffeine-induced arousal. Nat Sci Sleep. 2010;2:221-231. PMID 23616711 Preclinical
- Duan K et al. Dietary zinc acts as a sleep modulator. Nutrients. 2017;9:1108. PMID 29113075 RCT
- Suhyeon Kim et al. GABA/L-theanine mixture synergistically improves sleep in rodents. Phytomedicine. 2020;76:153236. PMID 31953122 Preclinical
- Arendt J. Melatonin and human circadian rhythms—therapeutic use in jet-lag. Chronobiol Int. 2018;35:758-774. PMID 29523065 RCT
Reference Interpretation:
- ✔Science-Backed: Every claim is grounded in peer-reviewed research.
- ✔Transparent: Full citations with evidence-level badges allow verification.
- ✔Trusted: Formulated with ingredients that have decades of safe use.
Study Limitations & Disclosures
Study Limitations
Open-label design; small sample size (n=10); single-night assessment for acute effects; self-reported outcomes subject to recall bias; ingredient-level evidence does not guarantee formulation-level efficacy; no direct comparison to active controls; pilot data are preliminary and require validation in a randomized, placebo-controlled trial.
Conflict of Interest & Funding
This study was funded by immunizeLABS. Authors are employees/shareholders of immunizeLABS. De-identified pilot data available upon reasonable request to corresponding author.
Disclaimer
These statements have not been evaluated by the Food and Drug Administration. DeepSleep™ is a dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease. This product is not intended to replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or sleep disorder.
Please consult your healthcare provider before use, especially if you are pregnant, nursing, taking medications (particularly sedatives, antidepressants, or blood pressure medications), or managing medical conditions.
Clinical Guidance:
- ✔Supplement, Not Drug: Supports natural sleep processes; not a pharmaceutical intervention.
- ✔Consult Your Doctor: Always discuss new supplements with your healthcare provider.
- ✔Safe When Used as Directed: Follow dosage instructions for optimal, comfortable results.
© 2026 immunizeLABS. All rights reserved.
Contact: sales@immunizelabs.com